208 related articles for article (PubMed ID: 2201691)
1. Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2.
Tomasselli AG; Hui JO; Sawyer TK; Staples DJ; Bannow C; Reardon IM; Howe WJ; DeCamp DL; Craik CS; Heinrikson RL
J Biol Chem; 1990 Aug; 265(24):14675-83. PubMed ID: 2201691
[TBL] [Abstract][Full Text] [Related]
2. Interdomain hydrolysis of a truncated Pseudomonas exotoxin by the human immunodeficiency virus-1 protease.
Tomasselli AG; Hui JO; Sawyer TK; Staples DJ; FitzGerald DJ; Chaudhary VK; Pastan I; Heinrikson RL
J Biol Chem; 1990 Jan; 265(1):408-13. PubMed ID: 2104621
[TBL] [Abstract][Full Text] [Related]
3. Proteases from human immunodeficiency virus and avian myeloblastosis virus show distinct specificities in hydrolysis of multidomain protein substrates.
Tomasselli AG; Hui JO; Sawyer TK; Staples DJ; Bannow CA; Reardon IM; Chaudhary VK; Fryling CM; Pastan I; Fitzgerald DJ
J Virol; 1990 Jul; 64(7):3157-61. PubMed ID: 2161935
[TBL] [Abstract][Full Text] [Related]
4. Substrate analogue inhibition and active site titration of purified recombinant HIV-1 protease.
Tomasselli AG; Olsen MK; Hui JO; Staples DJ; Sawyer TK; Heinrikson RL; Tomich CS
Biochemistry; 1990 Jan; 29(1):264-9. PubMed ID: 2182116
[TBL] [Abstract][Full Text] [Related]
5. Molecular basis for the relative substrate specificity of human immunodeficiency virus type 1 and feline immunodeficiency virus proteases.
Beck ZQ; Lin YC; Elder JH
J Virol; 2001 Oct; 75(19):9458-69. PubMed ID: 11533208
[TBL] [Abstract][Full Text] [Related]
6. Substitutions at the P2' site of gag p17-p24 affect cleavage efficiency by HIV-1 protease.
Margolin N; Heath W; Osborne E; Lai M; Vlahos C
Biochem Biophys Res Commun; 1990 Mar; 167(2):554-60. PubMed ID: 2182016
[TBL] [Abstract][Full Text] [Related]
7. Sensitive, soluble chromogenic substrates for HIV-1 proteinase.
Richards AD; Phylip LH; Farmerie WG; Scarborough PE; Alvarez A; Dunn BM; Hirel PH; Konvalinka J; Strop P; Pavlickova L
J Biol Chem; 1990 May; 265(14):7733-6. PubMed ID: 2186027
[TBL] [Abstract][Full Text] [Related]
8. Sub-site preferences of the aspartic proteinase from the human immunodeficiency virus, HIV-1.
Konvalinka J; Strop P; Velek J; Cerna V; Kostka V; Phylip LH; Richards AD; Dunn BM; Kay J
FEBS Lett; 1990 Jul; 268(1):35-8. PubMed ID: 2200711
[TBL] [Abstract][Full Text] [Related]
9. Substitution of proline with pipecolic acid at the scissile bond converts a peptide substrate of HIV proteinase into a selective inhibitor.
Copeland TD; Wondrak EM; Tozser J; Roberts MM; Oroszlan S
Biochem Biophys Res Commun; 1990 May; 169(1):310-4. PubMed ID: 2190554
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, X-ray crystallography, and infected T-cell assays.
Dreyer GB; Lambert DM; Meek TD; Carr TJ; Tomaszek TA; Fernandez AV; Bartus H; Cacciavillani E; Hassell AM; Minnich M
Biochemistry; 1992 Jul; 31(29):6646-59. PubMed ID: 1637805
[TBL] [Abstract][Full Text] [Related]
11. Recombinant HIV2 protease processes HIV1 Pr53gag and analogous junction peptides in vitro.
Pichuantes S; Babé LM; Barr PJ; DeCamp DL; Craik CS
J Biol Chem; 1990 Aug; 265(23):13890-8. PubMed ID: 2199446
[TBL] [Abstract][Full Text] [Related]
12. Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer.
Matayoshi ED; Wang GT; Krafft GA; Erickson J
Science; 1990 Feb; 247(4945):954-8. PubMed ID: 2106161
[TBL] [Abstract][Full Text] [Related]
13. Kinetic and modeling studies of S3-S3' subsites of HIV proteinases.
Tözsér J; Weber IT; Gustchina A; Bláha I; Copeland TD; Louis JM; Oroszlan S
Biochemistry; 1992 May; 31(20):4793-800. PubMed ID: 1591240
[TBL] [Abstract][Full Text] [Related]
14. Design, structure-activity, and molecular modeling studies of potent renin inhibitory peptides having N-terminal Nin-For-Trp (Ftr): angiotensinogen congeners modified by P1-P1' Phe-Phe, Sta, Leu psi[CH(OH)CH2]Val or leu psi[CH2NH]Val substitutions.
Sawyer TK; Pals DT; Mao B; Staples DJ; de Vaux AE; Maggiora LL; Affholter JA; Kati W; Duchamp D; Hester JB
J Med Chem; 1988 Jan; 31(1):18-30. PubMed ID: 3275777
[TBL] [Abstract][Full Text] [Related]
15. Different requirements for productive interaction between the active site of HIV-1 proteinase and substrates containing -hydrophobic*hydrophobic- or -aromatic*pro- cleavage sites.
Griffiths JT; Phylip LH; Konvalinka J; Strop P; Gustchina A; Wlodawer A; Davenport RJ; Briggs R; Dunn BM; Kay J
Biochemistry; 1992 Jun; 31(22):5193-200. PubMed ID: 1606143
[TBL] [Abstract][Full Text] [Related]
16. Mutational analysis of a native substrate of the human immunodeficiency virus type 1 proteinase.
Partin K; Kräusslich HG; Ehrlich L; Wimmer E; Carter C
J Virol; 1990 Aug; 64(8):3938-47. PubMed ID: 2196384
[TBL] [Abstract][Full Text] [Related]
17. Hydrolysis of synthetic chromogenic substrates by HIV-1 and HIV-2 proteinases.
Phylip LH; Richards AD; Kay J; Kovalinka J; Strop P; Blaha I; Velek J; Kostka V; Ritchie AJ; Broadhurst AV
Biochem Biophys Res Commun; 1990 Aug; 171(1):439-44. PubMed ID: 2203349
[TBL] [Abstract][Full Text] [Related]
18. Studies on the role of the S4 substrate binding site of HIV proteinases.
Tözsér J; Gustchina A; Weber IT; Blaha I; Wondrak EM; Oroszlan S
FEBS Lett; 1991 Feb; 279(2):356-60. PubMed ID: 2001747
[TBL] [Abstract][Full Text] [Related]
19. The crystallographic structure of the protease from human immunodeficiency virus type 2 with two synthetic peptidic transition state analog inhibitors.
Mulichak AM; Hui JO; Tomasselli AG; Heinrikson RL; Curry KA; Tomich CS; Thaisrivongs S; Sawyer TK; Watenpaugh KD
J Biol Chem; 1993 Jun; 268(18):13103-9. PubMed ID: 8514751
[TBL] [Abstract][Full Text] [Related]
20. Substrate specificity of cucumisin on synthetic peptides.
Yonezawa H; Kaizuka H; Uchikoba T; Arima K; Kaneda M
Biosci Biotechnol Biochem; 2000 Oct; 64(10):2104-8. PubMed ID: 11129582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
